Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that...

Michael White, Ph.D. joins Samumed as Chief Scientific Officer SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...